Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib plus atezolizumab vs pembrolizumab in untreated BRAF V600 wild-type advanced melanoma
2016-004387-18Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma and cutaneous malignancy comparing Cobimetinib + atezolizumab with Pembrolizumab (2 arms). Primary endpoint: Progression-free survival by independent review committee. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on 2016-004387-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004387-18.